How tumor-specific modulation frequencies were discovered

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In the spring of 2001, I visited a longtime friend and collaborator, Alexandre Barbault, to share with him my vision of using low levels radiofrequency electromagnetic fields for the treatment of cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Boris C. Pasche
Charles L. Spurr Professor of Medicine, Chairman, Department of Cancer Biology; Director, Comprehensive Cancer Center of Wake Forest University

YOU MAY BE INTERESTED IN

The NHS-Galleri trial presented at ASCO was the largest, prospective, randomized trial of a multicancer early detection test (MCED) to date. The study enrolled approximately 143,000 asymptomatic adults (ages 50-77) and was the first of its kind to assess clinical utility of an MCED test for cancer screening. 
Boris C. Pasche
Charles L. Spurr Professor of Medicine, Chairman, Department of Cancer Biology; Director, Comprehensive Cancer Center of Wake Forest University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login